Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential. - sprookjes - yvandenbroek - TriplyDB

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

http://www.wikidata.org/entity/Q34556427

about

Medications for substance use disorders (SUD): emerging approaches.

P2860

Q47731975-05BA5485-87C5-49E0-B27D-B16E57FC6AFC

P2860

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

http://www.wikidata.org/entity/Q34556427

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@ast

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@en

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@nl

type

label

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@ast

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@en

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@nl

prefLabel

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@ast

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@en

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@nl

P1433

Q34556427-ADE4B690-5593-4200-B8F7-0736D76283B3

P1476

Q34556427-D57081B7-A100-40D7-80A0-78455CB82889

P2093

Q34556427-06D85B7D-5CE0-4ED8-A032-8318552FA7E0

Q34556427-1C18A3CC-9B6E-46ED-A511-7CB2B5D40E1B

Q34556427-1F708F38-9741-40B8-B9FA-412AD7F16F51

Q34556427-4520D1C4-B83D-4ADF-B7EE-E06B2E296ED3

Q34556427-5D80B87A-4F68-42E8-A9F7-7C142CB74553

Q34556427-8FE5529A-ABC9-486D-B67A-F1437D8E0E17

Q34556427-9D4E4B0E-4F4F-4B1B-99CE-6D9D4C3792C0

Q34556427-A980E5AF-AB04-42E3-92ED-717E72710B8C

Q34556427-CA49293B-2E07-4DE0-A663-613455FBABDE

P2860

Q34556427-0BAD4BDB-5060-4F90-92BE-8D7653D7F4F2

Q34556427-0F9FF543-B818-43CD-912B-9B95A85AE077

Q34556427-1024C82F-F7D8-46CE-BC5D-8BC996372CD5

Q34556427-1285D580-0A34-465E-8844-0B28ECC3C349

Q34556427-1C8E16E3-0C8E-488F-A13B-573933D4C9CB

Q34556427-2D9A0FCB-77B0-400A-A1FE-801D13DE0BA5

Q34556427-3273A559-D8D9-4F77-9178-CAB5D579078D

Q34556427-373FC38D-9378-408B-AF58-59FD84C8A516

Q34556427-3CB3DBAD-3E50-4261-86E9-F52171952D9E

Q34556427-422EB9D8-D20D-4C29-82AF-991DAB1F631A

P2888

Q34556427-FFFEB445-D141-4CC6-837E-2C7135556A9C

P304

Q34556427-B15AD5C1-86EE-4584-9499-F2BF4DB7247D

P31

Q34556427-B81AA7E7-9082-4768-81EA-ED8DEDAEC879

P356

Q34556427-8FD916DA-6D3F-44C8-BCE7-563BDBB7CFD5

P407

Q34556427-DF380452-7474-408A-A25B-E0EAF5CD0B20

P433

Q34556427-B03F3408-60DE-4D4D-B099-7070CBB1B72E

P478

Q34556427-A4AD293D-D915-4ECA-B3DA-E2710B979461

P50

Q34556427-49CA624A-3327-43E0-AAC4-79A2447A8AB3

Q34556427-C6EBF748-517F-4214-A368-F3E3016CD830

P577

Q34556427-EDAE5C18-501F-4545-992F-96B227EB889B

P6179

Q34556427-045AE592-9E1E-4383-86A5-582DE0663368

P698

Q34556427-C94BE02F-EDCD-467F-BA62-8B61E91AFBE9

P932

Q34556427-425D80A9-B001-4329-B22E-8D68D716A925

P356

P1433

Molecular Psychiatry

P1476

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

@en

P2093

A J Sandweiss

http://www.w3.org/2001/XMLSchema#string

A K Giri

http://www.w3.org/2001/XMLSchema#string

J Hu

http://www.w3.org/2001/XMLSchema#string

M I McIntosh

http://www.w3.org/2001/XMLSchema#string

R Davidson-Knapp

http://www.w3.org/2001/XMLSchema#string

T M Largent-Milnes

http://www.w3.org/2001/XMLSchema#string

T W Vanderah

http://www.w3.org/2001/XMLSchema#string

T Yamamoto

http://www.w3.org/2001/XMLSchema#string

V J Hruby

http://www.w3.org/2001/XMLSchema#string

P2860

Genome engineering using the CRISPR-Cas9 system

Treatment of Opioid-Use Disorders

The pharmacology of neurokinin receptors in addiction: prospects for therapy

Neurokinin 1 receptor antagonism as a possible therapy for alcoholism

Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance

DNA targeting specificity of RNA-guided Cas9 nucleases

A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia

Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord.

A rapid and general assay for monitoring endogenous gene modification.

An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat.

P2888

P304

1745-1755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MP.2017.102

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085224990

http://www.w3.org/2001/XMLSchema#string

P698

28485408

http://www.w3.org/2001/XMLSchema#string

P932

5680162

http://www.w3.org/2001/XMLSchema#string